Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DKN-01 |
Synonyms | |
Therapy Description |
DKN-01 is a monoclonal antibody that binds to and inhibits Dkk1, a Wnt receptor antagonist, resulting in restoration of Wnt signaling and tumor growth inhibition (PMID: 28731148, PMID: 32192732). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DKN-01 | DKN 01|DKN01 | WNT Inhibitor 16 | DKN-01 is a monoclonal antibody that binds to and inhibits Dkk1, a Wnt receptor antagonist, resulting in restoration of Wnt signaling and tumor growth inhibition (PMID: 28731148, PMID: 32192732). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04681248 | Expanded access | DKN-01 | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | Available | USA | 0 |
NCT03837353 | Phase Ib/II | DKN-01 DKN-01 + Docetaxel | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 | Terminated | USA | 0 |
NCT03395080 | Phase II | DKN-01 DKN-01 + Paclitaxel | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204) (P204) | Completed | USA | 0 |